Antibody-complement-mediated cytotoxicity is enhanced by ribosome-inactivating proteins

Area of Science:

• Immunology
• Biotechnology
• Cell Biology

Background:

• Antibody-mediated cytotoxicity of complement is a key immune mechanism.
• Ribosome-inactivating proteins (RIPs) like gelonin and PAP-S possess cytotoxic properties.
• Targeting specific cell surface antigens with monoclonal antibodies can initiate complement-dependent cell lysis.

Purpose of the Study:

• To investigate the synergistic effect of RIPs (gelonin and PAP-S) with antibody-complement mediated cytotoxicity.
• To evaluate the potential of this combined approach for targeted cell elimination.
• To assess the efficacy in reducing viable human lymphoid cells expressing the common acute lymphoblastic leukemia antigen (CALLA).

Main Methods:

• Treatment of human lymphoid cells (expressing CALLA) with an anti-CALLA monoclonal antibody (J5).
• Subsequent incubation with rabbit complement.
• Addition of sublethal concentrations of gelonin or PAP-S during the treatment process.
• Quantification of remaining viable cells post-treatment.

Main Results:

• Standard antibody-complement treatment (J5 + rabbit complement) resulted in approximately 6% cell survival.
• The addition of gelonin reduced cell survival to about 0.02%.
• The addition of PAP-S reduced cell survival to about 0.3%.

Conclusions:

• Gelonin and PAP-S significantly potentiate antibody-complement mediated cell killing.
• This synergistic effect demonstrates a potential method for the in vitro elimination of malignant cells.
• The approach may be applicable for depleting immunocompetent cells from bone marrow prior to transplantation.